Ipsen’s Botox rival Dysport posts dual ph. 3 wins in migraine
Ipsen’s Botox rival Dysport posts dual ph. 3 wins in migraine (Fierce Pharma.)
Ipsen
Ipsen is a global specialty biopharmaceutical company focused on oncology, rare disease, and neuroscience, with a portfolio of in-market products including Dysport (botulinum toxin), Somatuline (lanreotide), and Onivyde (irinotecan). The company is advancing a refreshed R&D pipeline in 2026 with multiple Phase 3 readouts planned, alongside a new wave of partnership-led discovery deals.
Company Info
Sector:Pharmaceutical / Specialty Therapeutics
Headquarters:Paris, France (with major operations in the U.S. and U.K.)
Founded:1929
Website:www.ipsen.com/
Upcoming Milestones & Key Dates
H2 2026
Clinical Trial
Phase 3 RESOLVE readout of Onivyde in first-line metastatic pancreatic cancer
Q3 2026
Earnings
H1 2026 earnings and pipeline update
Clinical Development Pipeline
Onivyde (irinotecan) + chemotherapy regimens
Target: Topoisomerase I inhibitor liposomal formulationCabozantinib-based combinations
Target: Multi-kinase inhibitor (c-MET, VEGFR2, AXL)Tovorafenib (Ojemda)
Target: Type II RAF kinase inhibitorRecent News
Ipsen charts $1.75bn course for Kartos acquisition
Ipsen charts $1.75bn course for Kartos acquisition. (Pharmaphorum.)
Ipsen pens €700M deal to buy Swiss biotech for rare disease drug
Ipsen pens €700M deal to buy Swiss biotech for rare disease drug — Fierce Biotech coverage of biopharma industry developments.
Ipsen sends clear Memo to rare diseases with up to $796M buyout
Ipsen sends clear Memo to rare diseases with up to $796M buyout. (BioSpace.)
Ipsen to scoop up Memo Therapeutics and its kidney infection drug
Ipsen to scoop up Memo Therapeutics and its kidney infection drug
Ipsen's $450M blood cancer drug; FDA selects first cohort for pre-check pilot program
Ipsen's $450M blood cancer drug; FDA selects first cohort for "pre-check" pilot program. (BioPharma Dive.)
Ipsen makes up to $1.75B blood cancer bet with Kartos buyout
BioSpace reports on Ipsen's agreement to acquire Kartos Therapeutics in a deal worth up to $1.75B, expanding its hematology pipeline with a blood-cancer candidate.
Ipsen makes up to $1.75B blood cancer bet with Kartos buyout
Ipsen makes up to $1.75B blood cancer bet with Kartos buyout.
Ipsen's $450M blood cancer drug; FDA selects first cohort for pre-check pilot program
Ipsen's $450M blood cancer drug; FDA selects first cohort for pre-check pilot program (BioPharma Dive.)
Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M deal
Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M deal
Ipsen R&D Chief on Pipeline Discipline, Partnerships, and 2026 Milestones
Ipsen's head of R&D outlined the French pharma's 2026 pipeline priorities, including expected Phase 3 readouts in oncology and rare disease, plus a new wave of partnership-led discovery deals.
Leadership Team
Careers & Job Openings